Immuno-Oncology

The AJMC^® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.

Latest News

The findings can help guide ongoing and future clinical trials to help solve remaining challenges in LS-SCLC. | Image credit: Jennifer - stock.adobe

Neoadjuvant Immunotherapy Plus Chemotherapy Shows Promise in LS-SCLC

By Jared Kaltwasser

August 31st 2025

The findings may inform future studies on the therapeutic strategy for patients with small cell lung cancer (SCLC).

As SCLC continues to pose a therapeutic challenge due to rapid progression and early metastasis, the convergence of immunotherapy and precision radiation holds promise to extend survival and improve outcomes. | Image credit: mi_viri - stock.adobe.com

Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

By AJMC Contributor

July 29th 2025

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com

Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

By Kimberly Rath, PharmD

June 27th 2025

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com

FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

cancer vaccine | Image credit: IO Biotech

From “Super Skeptical” Beginnings, a New Immune-Modulatory Vaccine Awaits Phase 3 Results

By Mary Caffrey

May 3rd 2025

More News

May 5th 2023

COA Surveys Practices on EOM Interest Amid Changing Times in Community Oncology

An expert panel at the recent meeting of the Quality Cancer Care Alliance discussed the Enhancing Oncology Model (EOM), which is set to begin on July 1, 2023.

Patients With Advanced Cancer With High TMB Show Favorable Outcomes on ICIs

May 5th 2023

Patients With Advanced Cancer With High TMB Show Favorable Outcomes on ICIs

A recent study found that patients with advanced solid cancers with high tumor mutational burden (TMB) saw improved outcomes on immune checkpoint inhibitors (ICIs) compared with patients who had low-TMB cancers.

Personalized mRNA Cancer Vaccine With Pembrolizumab Significantly Prolonged Recurrence Free Survival in Resected High-risk Melanoma

April 27th 2023

Personalized mRNA Cancer Vaccine With Pembrolizumab Significantly Prolonged Recurrence Free Survival in Resected High-risk Melanoma

Alana Hippensteele, MA

These study results are the first to demonstrate randomized evidence that a personalized neoantigen approach could be beneficial for patients with cancer.

Shiela Plasencia, director of practice support, Community Oncology Alliance

April 18th 2023

Shiela Plasencia on the Use of Social Determinants Data Collection in Oncology Care

Shiela Plasencia, director of practice support at the Community Oncology Alliance, discusses the benefits of collecting social determinants of health data for both the patient and provider.

Moderna and Merck’s Cancer Vaccine Cuts Risk of Recurrence or Death 44% in Late-Stage, High-Risk Melanoma After Resection

April 16th 2023

Moderna and Merck’s Cancer Vaccine Cuts Risk of Recurrence or Death 44% in Late-Stage, High-Risk Melanoma After Resection

This combination is among the many cancer vaccine collaborations being pursued.

Immunotherapy word cloud: © ibreakstock - stock.adobe.com

April 15th 2023

Rural, Small Practices Slower to Adopt Immunotherapies

Immunotherapies are an important breakthrough in cancer treatment, but little is known about which practices adopt the therapy or the pace at which they do so.

Despite Potential Benefits, Barriers to CAR T-Cell Therapy for DLBCL Persist

April 13th 2023

Despite Potential Benefits, Barriers to CAR T-Cell Therapy for DLBCL Persist

Chimeric antigen receptor (CAR) T-cell therapies have shown efficacy and safety for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), but barriers to referral may obstruct patient access to them.

Early Recognition Key to Management of Immunotherapy Toxicities

April 11th 2023

Early Recognition Key to Management of Immunotherapy Toxicities

As much as immuno-oncology has been a leap forward, the ability to address immune-related adverse events is critical to making these therapies available in settings beyond academic centers; thus, the National Comprehensive Cancer Network offers clinical guidelines for management of toxicities.

Blood testing

April 8th 2023

DNA Sequencing Prior to HCT Identifies Patients at Risk of Poor AML Outcomes

A study of patients with acute myeloid leukemia (AML) in first remission found that the presence of certain variants indicative of measurable residual disease ahead of allogeneic hematopoietic cell transplant (HCT) was associated with relapse and worse survival.

April 5th 2023

FDA Approves Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma

The FDA has granted accelerated approval to enfortumab vedotin-ejfv plus pembrolizumab for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.

Jeremy Graff, Chief Scientific Officer, IMV

March 26th 2023

Delivery Matters: In Early Studies, DPX Technology Allows Vaccines to Persist When Cancer Pushes Back

Based on promising results, the biotech IMV has moved into phase 2b trials with a cancer vaccine composed of survivin epitopes that uses the company’s proprietary delivery system to elicit persistent immune responses.

Axi-Cel Improves Overall Survival vs Standard-of-Care Initial Treatment for R/R LBCL

March 21st 2023

Axi-Cel Improves Overall Survival vs Standard-of-Care Initial Treatment for R/R LBCL

A prespecified overall survival analysis of the phase 3 ZUMA-7 trial found that axicabtagene ciloleucel (axi-cel) led to better outcomes vs the historical standard of care for relapsed or refractory large B-cell lymphoma (R/R LBCL).

Needle and vaccine

March 16th 2023

Study Shows Immune Response After COVID-19 Vaccine in Majority of Patients Treated With CAR T-Cell Therapy

The majority of CAR T-cell therapy recipients developed a humoral immune response to vaccination against SARS-CoV-2 in a recent study, with a more robust vaccine schedule linked to higher antibody titers.

March 15th 2023

What We’re Reading: Biomarker Testing in Kentucky; Opioid Guidelines Updated; EPA Limits in Drinking Water

Kentucky passes a bill to require insurers to cover biomarker tests for patients with cancer; CDC opioid guidelines updated in November may be too late for patients with chronic pain; the Environmental Protection Agency is proposing new limits to reduce dangerous human-manufactured chemicals in drinking water.

Kidneys

March 8th 2023

Lenvatinib Plus Pembrolizumab Shows Durable Efficacy Benefits vs Sunitinib in Renal Cell Carcinoma

The extended follow-up results are consistent with the primary analysis of the CLEAR trial, supporting the increased efficacy of first-line lenvatinib plus pembrolizumab compared with sunitinib in patients with advanced renal cell carcinoma.

Sashi Naidu, MD, Carolina Blood and Cancer Care Associates

March 6th 2023

Dr Sashi Naidu: Partnering With Molecular Diagnostic Labs Facilitates Advanced Cancer Care

Carolina Blood and Cancer Care Associates’ No One Left Alone initiative works to dismantle cancer health disparities and increase health care equity among its rural patient population. Sashi Naidu, MD, director of research, discusses delivering next-generation sequencing testing to patients.

Skin cancer

March 1st 2023

Neoadjuvant Initiation of Pembrolizumab Improves Outcomes vs Adjuvant Therapy Alone in Advanced Melanoma

Starting immunotherapy prior to surgical resection led to better outcomes vs standard, adjuvant-only immunotherapy in a phase 2 trial of patients with advanced melanoma.

With Broad Input, Clinical Pathways Making a Difference for End Users

February 23rd 2023

With Broad Input, Clinical Pathways Making a Difference for End Users

Sequencing, Sustainability Are Hot Topics in CAR T- and Gene Cell Therapies Discussion

February 23rd 2023

Sequencing, Sustainability Are Hot Topics in CAR T- and Gene Cell Therapies Discussion

Breast cancer

February 22nd 2023

Oncolytic Virus Therapy Shows Promising Results in Early-Stage TNBC

Results from a phase 2 study suggests that the oncolytic virus talimogene laherparepvec has potential to improve therapy responses for patients undergoing neoadjuvant chemotherapy for triple-negative breast cancer (TNBC).

Andrew Hertler, MD, FACP

February 20th 2023

New Century Health’s Andrew Hertler, MD, FACP: “You Have to Be Careful When You Look at Total Cost of Care”

Interview by Mary Caffrey

CAR T cells

February 18th 2023

Study Suggests Second-line Axi-Cel Is Cost-effective vs Standard Care in R/R DLBCL

Despite coming at a high cost, an analysis found that in some cases, chimeric antigen receptor T-cell therapy may be cost-effective compared with the standard of care in the second line or later for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

Kidneys

February 16th 2023

After More Than 3 Years, Nivolumab With Cabozantinib Shows Sustained Response Over Sunitinib in RCC

Long-term results show sustained benefit from the immunotherapy-TKI combination for patients with metastatic renal cell carcinoma regardless of risk profile or PD-L1 status.

Brexucabtagene Autoleucel Shows High Rate of Durable Response at 3 Years

February 9th 2023

Brexucabtagene Autoleucel Shows High Rate of Durable Response at 3 Years

Allison Inserro

Chimeric antigen receptor T-cell therapy brexucabtagene autoleucel showed a rate of complete remission of 71% and a rate of complete remission with incomplete hematologic recovery of 56%, according to 3-year follow-up results.

Esophageal cancer

February 7th 2023

Zanidatamab, With Biparatopic Binding to HER2, Shows 84% OS in Phase 2 Study of Gastroesophageal Adenocarcinoma

The investigational therapy promises a new way to target HER2 while still using chemotherapy combinations.

Dr Jeremy Abramson Discusses CAR T-Cell Therapy Timing in DLBCL

February 4th 2023

Dr Jeremy Abramson Discusses CAR T-Cell Therapy Timing in DLBCL

Hayden E. Klein Rose McNulty

Jeremy Abramson, MD, director of the Jon and Jo Ann Hagler Center for Lymphoma at the Massachusetts General Hospital Cancer Center, shared his take on the potential benefits of chimeric antigen receptor (CAR) T-cell therapy in earlier lines of treatment.

Study Finds Link Between Tumor Microbiome and Immunotherapy Outcomes in Soft Tissue Sarcoma

February 3rd 2023

Study Finds Link Between Tumor Microbiome and Immunotherapy Outcomes in Soft Tissue Sarcoma

The study suggests there is measurable amount of microbiome within the soft tissue sarcoma tumor environment, which was previously thought to be sterile.

'Persistent' Subset of Tumor Mutations May Predict Immunotherapy Response

January 26th 2023

"Persistent" Subset of Tumor Mutations May Predict Immunotherapy Response

A study published in Nature Medicine found that certain tumor mutations are more persistent and may predict immunotherapy responses more reliably than overall tumor mutational burden.

Lymphoma cell

January 19th 2023

Axi-cel Shows Improved Quality-Adjusted Survival Versus Standard of Care in LBCL

A Q-TWiST analysis of ZUMA-7 trial data suggests that axicabtagene ciloleucel (axi-cel) in the second line is beneficial to quality-adjusted survival and is a viable option for patients with relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy.

Dr Alonso V. Pacheco

January 17th 2023

There Is a Need to Identify Patients Most Likely to Benefit From Immunotherapies, Says Dr Alonso V. Pacheco

Laura Joszt, MA Justina Petrullo

New immunotherapies are changing the shape of oncology care, but there is also a need for a system that provides these high-quality therapies to the patients most likely to benefit from them. This might mean doing an assessment and a deeper dive into patient functional status, says Alonso V. Pacheco, MD, medical director and medical oncologist/hematologist, Rocky Mountain Cancer Centers.

<1 2 3 4 5 6 7 8

...

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions